GlassScriptPhysician profile
Jane G Sugar
NPI 1770724759
$1,386.14
in general payments reported to CMS, 2019-2025
27 companies · $430 in 2025
The $430 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.08 · 2021: $11.50 · 2022: $250 · 2023: $334 · 2024: $314 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,057 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,056.58 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merit Medical Systems INC | $349.55 | 2021-2023 | Savi Scout |
| Daiichi Sankyo INC. | $161.79 | 2023-2025 | Enhertu |
| Stryker Corporation | $95.97 | 2025 | Molli, Spy-Phi System |
| Stemline Therapeutics INC. | $91.58 | 2023-2025 | Orserdu |
| Genmab U.S., INC. | $84.95 | 2023-2025 | Tivdak, Epkinly |
| Recordati_rare_diseases_inc. | $73.17 | 2024-2025 | Sylvant |
| Astrazeneca Pharmaceuticals LP | $70.32 | 2023-2024 | Enhertu |
| Merck Sharp & Dohme LLC | $50.23 | 2023-2025 | Lynparza, Keytruda |
| Apellis Pharmaceuticals, INC. | $48.75 | 2024-2025 | Empaveli |
| Ethicon US, LLC | $29.22 | 2023 | Dermabond Prineo, Ethicon, Vistaseal |
| Davol INC. | $26.17 | 2019 | |
| Leica Microsystems INC. | $23.73 | 2024 | Mammotome Revolve |
| Elucent Medical | $22.65 | 2025 | |
| Geron Corporation | $21.42 | 2025 | Rytelo |
| Kci USA, INC. | $21.00 | 2023 | Prevena |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $20.91 | 2019 | |
| Caris Mpi, INC. | $20.57 | 2025 | Mi Cancer Seek |
| Genentech USA, INC. | $20.51 | 2025 | Itovebi |
| Servier Pharmaceuticals LLC | $20.51 | 2024 | |
| Amgen INC. | $19.80 | 2023 | Xgeva |
| Tersera Therapeutics LLC | $18.96 | 2025 | Zoladex |
| Aveo Pharmaceuticals, INC. | $17.86 | 2025 | |
| Sanara Medtech INC. | $16.89 | 2022 | |
| Seagen INC. | $16.26 | 2023 | Tukysa |
| Emd Serono, INC. | $14.71 | 2024 | |
| Tactile Systems Technology INC | $14.66 | 2022 | |
| Puma Biotechnology, INC. | $14.00 | 2023 | Nerlynx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Sugar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.